Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Trametinib Dimethyl Sulfoxide Patent Expiration

Trametinib Dimethyl Sulfoxide is used for treating various cancers, including melanoma, anaplastic thyroid cancer, non-small cell lung cancer, and low-grade glioma, in combination with dabrafenib. It was first introduced by Novartis Pharmaceuticals Corp in its drug Mekinist on May 29, 2013. 2 different companies have introduced drugs containing Trametinib Dimethyl Sulfoxide.


Trametinib Dimethyl Sulfoxide Patents

Given below is the list of patents protecting Trametinib Dimethyl Sulfoxide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Mekinist US10869869

(Pediatric)

 Method of adjuvant cancer treatment Mar 02, 2034 Novartis
Mekinist US10869869 Method of adjuvant cancer treatment Aug 30, 2033 Novartis
Mekinist US8580304

(Pediatric)

 Pharmaceutical composition Jul 28, 2032 Novartis
Mekinist US9155706

(Pediatric)

 Pharmaceutical composition Jul 28, 2032 Novartis
Mekinist US9271941

(Pediatric)

 Pharmaceutical composition Jul 28, 2032 Novartis
Mekinist US9399021

(Pediatric)

 Pharmaceutical composition Jul 28, 2032 Novartis
Mekinist US8580304 Pharmaceutical composition Jan 28, 2032 Novartis
Mekinist US9155706 Pharmaceutical composition Jan 28, 2032 Novartis
Mekinist US9271941 Pharmaceutical composition Jan 28, 2032 Novartis
Mekinist US9399021 Pharmaceutical composition Jan 28, 2032 Novartis
Mekinist US8703781

(Pediatric)

 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors Apr 15, 2031 Novartis
Mekinist US8952018

(Pediatric)

 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Apr 15, 2031 Novartis
Mekinist US8703781 Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors Oct 15, 2030 Novartis
Mekinist US8952018 Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors Oct 15, 2030 Novartis
Mekinist US7378423

(Pediatric)

 Pyrimidine compound and medical use thereof Nov 29, 2027 Novartis
Mekinist US7378423 Pyrimidine compound and medical use thereof May 29, 2027 Novartis
Mekinist US8835443

(Pediatric)

 Pyrimidine compound and medical use thereof Dec 10, 2025 Novartis
Mekinist US8835443 Pyrimidine compound and medical use thereof Jun 10, 2025 Novartis



Trametinib Dimethyl Sulfoxide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Trametinib Dimethyl Sulfoxide Generic API Manufacturers

Several generic applications have been filed for Trametinib Dimethyl Sulfoxide.

Given below is the list of companies who have filed for Trametinib Dimethyl Sulfoxide generic, along with the locations of their manufacturing plants worldwide.


1. NOVUGEN

Novugen Oncology Sdn Bhd has filed for 2 different strengths of generic version for Trametinib Dimethyl Sulfoxide. Given below are the details of the strengths of this generic introduced by Novugen.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 0.5MG

tablet Discontinued ORAL N/A Aug 6, 2024
EQ 2MG

tablet Discontinued ORAL N/A Aug 6, 2024